Date Title
February 16, 2018
Realm Therapeutics - Block listing Interim Review
RNS Number : 3663E Realm Therapeutics PLC 16 February 2018   Realm Therapeutics plc Block Listing Interim Review   Pursuant to AIM Rule 29 and Schedule 6 of the AIM Rules for Companies Realm Therapeutics plc makes the following update on its block listing:   Date:   16 February 2018   Name of
February 15, 2018
Realm Therapeutics - Clinical and Business Update
RNS Number : 9394E Realm Therapeutics PLC 15 February 2018   Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones   Phase 2 Allergic Conjunctivitis Study Ahead of Schedule; Top-Line Results Anticipated by End of Q1   Phase 2 Atopic Dermatitis Study on Track with
January 2, 2018
Realm Therapeutics - Presents at 5th Annual Dermatology Summit
RNS Number : 5854A Realm Therapeutics PLC 02 January 2018   Realm Therapeutics to Present at the 5 th Annual Dermatology Summit   MALVERN, PA , January 2 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory
December 15, 2017
Realm Therapeutics - Director/PDMR Shareholding
RNS Number : 4271Z Realm Therapeutics PLC 15 December 2017   Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Grant of Options   15 December 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary
December 12, 2017
Realm Therapeutics - First Patient Dosed in Phase 2 Study of PR013
RNS Number : 0227Z Realm Therapeutics PLC 12 December 2017       Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR013 for the Treatment of Allergic Conjunctivitis     MALVERN, PA , December 12 2017 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company
December 5, 2017
Realm Therapeutics - First Patient Dosed in Phase 2 Study of PR022
RNS Number : 3601Y Realm Therapeutics PLC 05 December 2017     Realm Therapeutics Announces First Patient Dosed in Phase 2 Study of PR022 for the Treatment of Atopic Dermatitis     MALVERN, PA , 5 December 2017 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused
November 21, 2017
Realm Therapeutics - Realm: Preclinical Data on PR022 Published
RNS Number : 0370X Realm Therapeutics PLC 21 November 2017       Realm Therapeutics Announces Publication of Positive Preclinical Data on PR022 in the Treatment of Atopic Dermatitis   In Vivo and In Vitro Data Demonstrate Reduced Itch and Inflammation Progressing to Phase 2 trial in coming weeks  
November 17, 2017
Realm Therapeutics - Directorate Change
RNS Number : 7718W Realm Therapeutics PLC 17 November 2017   Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Realm Therapeutics Appoints Sandy Zweifach as Non-Executive Director & Non-Executive Directors Matthew Hammond and Daniel Hegglin Retire from the Board   17
November 2, 2017
Realm Therapeutics - Realm Therapeutics to Present at BIO-Europe® 2017
RNS Number : 2948V Realm Therapeutics PLC 02 November 2017     Realm Therapeutics to Present at BIO-Europe ® 2017   MALVERN, PA , November [2] 2017 - Realm Therapeutics plc (AIM: RLM), a clinical stage biopharmaceutical company focused on leveraging its proprietary immunomodulatory technology, is
October 30, 2017
Realm Therapeutics - Realm Presents Data at ACAAI Scientific Meeting
RNS Number : 8994U Realm Therapeutics PLC 30 October 2017       Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company")   Realm Therapeutics Presents Data Highlighting PR013's Efficacy Reducing Hyperemia and Pruritus Associated with Allergic Conjunctivitis at The American College of
Displaying 61 - 70 of 156

Search Investor Relations